|
A Class Act in Glaucoma Management: Differentiating Rho Kinase Inhibitors From the Pack
Medical management of glaucoma primarily focuses on lowering intraocular pressure (IOP) by decreasing aqueous production, reducing episcleral venous pressure, and/or increasing uveoscleral and trabecular outflow. Recently approved agents have expanded treatment options beyond the traditional mainstays of prostaglandin analogues and β-blockers, engaging Rho kinase (ROCK) inhibition to improve outcomes for patients with glaucoma. In this CE monograph, experts in the field will review the clinic... |
|
Glaucoma Treatments in 2021: Personalizing Patient Needs
This continuing medical education (CE/CME) activity captures content from a roundtable in August.
Activity Description
Based on a roundtable held in August, this supplement summarizes a discussion of the mechanisms of actions and challenges with currently available and novel therapeutics as well as how to personalize glaucoma treatments.
Target Audience
This certified CME/CE activity is designed eye care providers involved in the management of glaucoma and associated disorders. |
|
Individualizing Glaucoma Treatment: Understanding How to Utilize Traditional and Novel Agents
Join Nathan M. Radcliffe, MD, and Justin Schweitzer, OD, FAAO, as they discuss the ways in which novel therapeutics may help to overcome the challenges and limitations associated with currently available pharmacologic treatment options for ocular hypertension and primary open-angle glaucoma. |